CorMedix Inc. to Report Fourth Quarter and Full Year 2015 Financial Results

Conference Call to be held Wednesday, March 16, 2016 at 9 a.m. Eastern Time

BEDMINSTER, NJ / ACCESSWIRE / March 9, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it will issue its financial results for the fourth quarter and year ended December 31, 2015, after the market close on Tuesday, March 15, 2016.

CorMedix CEO, Randy Milby will host a conference call on Wednesday, March 16, 2016 at 9 a.m. Eastern time to discuss the financial results and recent corporate developments.

Please call five minutes before the conference call is scheduled to begin.
Dial-In (Toll Free) 877-407-9210
International Dial-In 201-689-8049

A replay of the teleconference will be available until 11:59 p.m. on March 23, 2016.
Replay Number: 877-660-6853
Replay International: 201-612-7415
Conference ID: 13632043

About Neutrolin®

Neutrolin® is a novel formulation of taurolidine, citrate and heparin 1000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis and biofilm to keep catheters operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation for oncology, hemodialysis, and intensive care patients. Neutrolin has CE mark approval for use in the European Union. The U.S. Food and Drug Administration (FDA) has designated Neutrolin as a Qualified Infectious Disease Product (QIDP), which provides an additional five years of market exclusivity in addition to the five years granted for a New Chemical Entity.

About CorMedix Inc.

CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated the U.S. pivotal trial of its novel anti-infective solution Neutrolin® for catheter related blood infections (CRBI). CRBIs represent a large significant medical need. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix’s first commercial product approved in Europe is Neutrolin®, an anti-infective solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. Neutrolin is a liquid formulation designed to prevent central venous catheter infection as well as catheter obstruction, also referred to as maintenance of catheter patency, in central venous catheters. CorMedix initiated a Phase 3 clinical study in the U.S. in the fourth quarter 2015. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also had designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information visit: www.cormedix.com.

For Investors & Media:

CorMedix
Maureen McEnroe, CFA: mmcenroe@machealthcare.com; (914) 588-1873

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

SOURCE: CorMedix Inc.

ReleaseID: 437616